Clinical Trials
Sorrento begin patient enrollment in phase 2 study of COVI-MSC to treat Covid-19 associated ARD in ICU patients
Sorrento Therapeutics, Inc. announced the start of enrollment in its Phase 2 efficacy study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS) in Brazil....
Clinical Trials
NRx’s Zyesami lowers respiratory distress in Phase IIb/III Covid-19 trial
NRx Pharmaceuticals has reported additional data from Phase IIb/III clinical trial where its drug, Zyesami (aviptadil), offered a rise in blood oxygen within a day in critical Covid-19 patients with acute respiratory failure.
Zyesami is a synthetic form of vasoactive...
Clinical Trials
Curevac’s CV2CoV Demonstrates Improved Immune Response And Protection In Preclinical Study
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, and GSK announced the publication of preclinical data investigating immune responses as well as the protective efficacy of CureVac’s first-generation vaccine...
Clinical Trials
Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced the initiation of a further Phase 3 trial (VLA2001-304) for its inactivated, adjuvanted COVID-19 vaccine...
Clinical Trials
AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
AzurRx BioPharma, Inc., a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, announced the completion of site initiation visits and the addition of five (5) new clinical trial sites in Ukraine for the...
Clinical Trials
Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced positive topline results from the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate,...
Clinical Trials
Lilly and Incyte’s baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation
Eli Lilly and Company and Incyte announced results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with COVID-19 on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) who received baricitinib plus standard...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read